Avalo Therapeutics (NASDAQ:AVTX) Insider Paul Varki Sells 75,063 Shares

Key Points

• Insider Paul Varki sold 75,063 shares at an average of $20.17 under a pre‑arranged Rule 10b5‑1 plan, generating about $1.514M and reducing his stake by 95.38% to 3,634 shares.
• Phase 2 LOTUS topline results met the primary endpoint for abdakibart, and Avalo priced an underwritten offering (~19.73M shares + pre‑funded warrants) at $17.75 to raise roughly $375M to fund a planned Phase 3, which cuts near‑term funding risk but is dilutive.
• Market reaction and analyst upgrades: shares traded up ~4.9% to $22.87 on heavy volume, multiple firms raised targets (e.g., BTIG to $58, Citizens/JMP to $62, Wedbush to $40), and the consensus rating is a "Moderate Buy" with a target near $48.14.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) insider Paul Varki sold 75,063 shares of the company's stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $20.17, for a total transaction of $1,514,020.71. Following the completion of the transaction, the insider owned 3,634 shares in the company, valued at approximately $73,297.78. This represents a 95.38% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics Stock Up 4.9%

Shares of NASDAQ AVTX traded up $1.06 during midday trading on Thursday, hitting $22.87. The stock had a trading volume of 5,741,760 shares, compared to its average volume of 967,018. The business's 50 day moving average is $15.47 and its 200-day moving average is $16.29. The company has a market cap of $610.95 million, a P/E ratio of -3.99 and a beta of 0.78. Avalo Therapeutics, Inc. has a 52 week low of $3.39 and a 52 week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $1.17. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of ($0.21) million. As a group, analysts expect that Avalo Therapeutics, Inc. will post -3.38 EPS for the current fiscal year.

Key Headlines Impacting Avalo Therapeutics

Here are the key news stories impacting Avalo Therapeutics this week:

• Positive Sentiment: Phase 2 LOTUS topline results met the primary endpoint (HiSCR75 at Week 16) for abdakibart with favorable secondary endpoints and safety; Avalo said it plans to advance to a registrational Phase 3 program — a direct clinical catalyst supporting upside. Phase 2/Financing Analysis
• Positive Sentiment: Avalo priced an underwritten public offering (~19.73M shares + pre‑funded warrants) at $17.75 to raise roughly $375M to advance abdakibart into Phase 3 and extend the cash runway — reduces near‑term funding risk for the program. Offering Press Release
• Positive Sentiment: Multiple analysts raised ratings/targets after the data: BTIG to $58, Citizens / JMP to $62 and Wedbush to $40 — increased sell‑side conviction can attract more buyers and institutional interest. BTIG Research Note
• Neutral Sentiment: Mainstream coverage noted sharp pre‑market and after‑hours moves as traders digested the clinical readout and offering—momentum headlines can amplify volatility but are not new fundamental information. MSN Pre‑Market Coverage
• Neutral Sentiment: After‑hours reporting also highlighted the clinical win and stock surge; useful for context but reflects market reaction rather than new data. MSN After‑Hours Coverage
• Negative Sentiment: Equity offering is dilutive — issuance at $17.75 versus recent market prices means existing shareholders will see dilution; watch final share count and underwriter option exercise. (See offering announcements above.)
• Negative Sentiment: Unusually large put‑option activity and continued insider selling have been reported, which could signal hedging/speculative positioning or management liquidity needs and add downside pressure amid post‑news volatility.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Avalo Therapeutics in a research note on Wednesday, April 8th. Citigroup restated an "outperform" rating on shares of Avalo Therapeutics in a research report on Wednesday. Wall Street Zen upgraded shares of Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Sunday, March 29th. BTIG Research increased their price objective on shares of Avalo Therapeutics from $40.00 to $58.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Wedbush increased their price objective on shares of Avalo Therapeutics from $29.00 to $40.00 and gave the company an "outperform" rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.14.

Institutional Trading of Avalo Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Patient Square Capital LP purchased a new stake in Avalo Therapeutics during the third quarter valued at approximately $1,271,000. Cantor Fitzgerald L. P. purchased a new stake in Avalo Therapeutics during the third quarter valued at approximately $1,083,000. Boothbay Fund Management LLC increased its holdings in Avalo Therapeutics by 1,916.6% during the third quarter. Boothbay Fund Management LLC now owns 228,297 shares of the company's stock valued at $2,902,000 after buying an additional 216,976 shares during the last quarter. Ally Bridge Group NY LLC purchased a new stake in shares of Avalo Therapeutics in the third quarter worth $2,264,000. Finally, Aberdeen Group plc purchased a new stake in shares of Avalo Therapeutics in the third quarter worth $925,000. 87.06% of the stock is owned by hedge funds and other institutional investors.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.